NAKODAR LIFESCIENCES UK LTD

Company Registration Number:
13758305 (England and Wales)

Unaudited statutory accounts for the year ended 30 November 2023

Period of accounts

Start date: 1 December 2022

End date: 30 November 2023

NAKODAR LIFESCIENCES UK LTD

Contents of the Financial Statements

for the Period Ended 30 November 2023

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes

NAKODAR LIFESCIENCES UK LTD

Directors' report period ended 30 November 2023

The directors present their report with the financial statements of the company for the period ended 30 November 2023

Principal activities of the company

Nakodar Lifesciences UK Ltd is primarily engaged in the business of providing high-quality medical products, healthcare solutions, and medical supplies to meet the needs of patients and healthcare providers. The company focuses on the development, manufacture, and distribution of a broad range of medical products, including infection control wipes, over-the-counter products, and specialized healthcare solutions.

Political and charitable donations

During the financial year, Nakodar Lifesciences UK Ltd did not make any political donations, nor did the company incur any political expenditure in accordance with the requirements under the Companies Act 2006.



Directors

The director shown below has held office during the whole of the period from
1 December 2022 to 30 November 2023

Ankur Mitroo


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
1 September 2024

And signed on behalf of the board by:
Name: Ankur Mitroo
Status: Director

NAKODAR LIFESCIENCES UK LTD

Profit And Loss Account

for the Period Ended 30 November 2023

2023 2022


£

£
Turnover: 5,000 0
Cost of sales: ( 4,500 ) 0
Gross profit(or loss): 500 0
Distribution costs: ( 500 ) 0
Administrative expenses: ( 500 ) 0
Other operating income: 0 0
Operating profit(or loss): (500) 0
Interest receivable and similar income: 0 0
Interest payable and similar charges: 0 0
Profit(or loss) before tax: (500) 0
Tax: 0 0
Profit(or loss) for the financial year: (500) 0

NAKODAR LIFESCIENCES UK LTD

Balance sheet

As at 30 November 2023

Notes 2023 2022


£

£
Called up share capital not paid: 0 0
Fixed assets
Intangible assets:   0 0
Tangible assets:   0 0
Investments:   0 0
Total fixed assets: 0 0
Current assets
Stocks: 3 10,000 0
Debtors: 4 7,000 0
Cash at bank and in hand: 5,500 4,000
Investments:   0 0
Total current assets: 22,500 4,000
Prepayments and accrued income: 0 0
Creditors: amounts falling due within one year:   0 0
Net current assets (liabilities): 22,500 4,000
Total assets less current liabilities: 22,500 4,000
Creditors: amounts falling due after more than one year:   0 0
Provision for liabilities: 0 0
Accruals and deferred income: 0 0
Total net assets (liabilities): 22,500 4,000
Capital and reserves
Called up share capital: 100 100
Share premium account: 0 0
Other reserves: 22,400 3,900
Profit and loss account: 0 0
Total Shareholders' funds: 22,500 4,000

The notes form part of these financial statements

NAKODAR LIFESCIENCES UK LTD

Balance sheet statements

For the year ending 30 November 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 1 September 2024
and signed on behalf of the board by:

Name: Ankur Mitroo
Status: Director

The notes form part of these financial statements

NAKODAR LIFESCIENCES UK LTD

Notes to the Financial Statements

for the Period Ended 30 November 2023

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

NAKODAR LIFESCIENCES UK LTD

Notes to the Financial Statements

for the Period Ended 30 November 2023

  • 2. Employees

    2023 2022
    Average number of employees during the period 3 1

NAKODAR LIFESCIENCES UK LTD

Notes to the Financial Statements

for the Period Ended 30 November 2023

3. Stocks

2023 2022
£ £
Stocks 10,000 0
Payments on account 0 0
Total 10,000 0

NAKODAR LIFESCIENCES UK LTD

Notes to the Financial Statements

for the Period Ended 30 November 2023

4. Debtors

2023 2022
£ £
Trade debtors 7,000 0
Prepayments and accrued income 0 0
Other debtors 0 0
Total 7,000 0
Debtors due after more than one year: 0 0